This is most likely due to the transient depletion of CCR2+ cells that reappear in peripheral blood shortly after ceasing the antibody treatment (Figure 6B) or tumor intrinsic adaptions alleviating the need for the CCR2/CCL2 axis. The gene discussed is CCL2; the disease is neoplasm.